Jove
Visualize
Contact Us

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

284
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
284

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Double Jeopardy: Thrombotic Thrombocytopenic Purpura in Systemic Mastocytosis-A Rare but Lethal Conundrum.

International journal of laboratory hematology·2026
Same author

Images in Vascular Medicine: Beyond the lesion - recognizing hematologic sequelae of venous malformations.

Vascular medicine (London, England)·2026
Same author

Pancreatic Plasmacytoma Post-Allogeneic-HSCT: Diagnosis by EUS-Guided Biopsy.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2026
Same author

Infection-related mortality after hematopoietic stem cell transplantation in a high antimicrobial resistance setting.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026
Same author

Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience

Turkish journal of haematology : official journal of Turkish Society of Haematology·2026
Same author

Exploring an independent association between rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone dose intensity and clinical outcomes in large B-cell lymphoma: Analyses of subsequent endpoints following a complete response in a real-world cohort of 1369 patients.

Cancer·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 6, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.2K

How to improve AML outcomes?

Taner Tan1, Sinem Civriz Bozdag2

  • 1Department of Hematology, ͣKoc University Medical School, Istanbul, Turkey.

Blood Research
|December 2, 2024
PubMed
Summary

Advances in understanding acute myeloid leukemia (AML) pathophysiology and genomics are leading to new treatments beyond the standard 7+3 regimen. Recent classifications emphasize AML

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Acute myeloid leukemia (AML) treatment has been dominated by the 7+3 regimen since the 1970s.
  • Recent advancements in understanding AML pathophysiology and genomic landscape are improving patient outcomes.
  • The 2022 World Health Organization and International Consensus Classification updates reflect molecular-level changes in AML definitions.

Purpose of the Study:

  • To highlight the evolving understanding of acute myeloid leukemia (AML) based on molecular and genetic characteristics.
  • To underscore the shift towards genetically-defined AML classifications.
  • To contextualize the development of novel therapeutic strategies beyond traditional chemotherapy.

Main Methods:

  • Review of current literature and classification guidelines for acute myeloid leukemia (AML).
Keywords:
AMLMutationsOutcomeRelapsedTargetedTreatment

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

1.8K

Related Experiment Videos

Last Updated: Jun 6, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.2K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

1.8K
  • Analysis of the impact of molecular profiling on AML understanding and treatment.
  • Retrospective study data on driver mutations in AML patients.

    • Main Results:

    • Acute myeloid leukemia (AML) is now recognized as a genetically diverse disease.
    • A retrospective study identified 5234 driver mutations across 76 genes/genomic regions.
    • 86% of AML patients exhibit two or more driver mutations, emphasizing genetic heterogeneity.

    Conclusions:

    • Modern AML classification is increasingly reliant on genetic characteristics.
    • Novel molecular targets are driving the development of new therapeutic strategies for AML.
    • The evolving understanding of AML genomics necessitates a move beyond historical treatment paradigms.